Reviva Pharmaceuticals Launches $50M At-Market Offering

Reviva Pharmaceuticals Holdings ( (RVPH) ) has shared an announcement.

On May 30, 2025, Reviva Pharmaceuticals Holdings, Inc. entered into an At Market Issuance Sales Agreement with B. Riley Securities, Inc. and Alliance Global Partners to facilitate an at-the-market offering program. This agreement allows the company to sell shares of its common stock, valued up to $50 million, through the agents on Nasdaq or other trading markets. The agents will use commercially reasonable efforts to sell the shares based on the company’s instructions, and the company will pay a commission of three percent on the gross sales proceeds.

The most recent analyst rating on (RVPH) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Reviva Pharmaceuticals Holdings stock, see the RVPH Stock Forecast page.

Spark’s Take on RVPH Stock

According to Spark, TipRanks’ AI Analyst, RVPH is a Underperform.

Reviva Pharmaceuticals Holdings faces significant financial challenges, with zero revenue, substantial net losses, and negative cash flows, heavily weighing down its stock score. The technical analysis indicates weak momentum and a downward trend, while the negative P/E ratio and lack of dividends reflect poor valuation. Recent corporate events show leadership confidence but do not mitigate the underlying financial distress.

To see Spark’s full report on RVPH stock, click here.

More about Reviva Pharmaceuticals Holdings

Average Trading Volume: 686,321

Technical Sentiment Signal: Sell

Current Market Cap: $41.65M

See more insights into RVPH stock on TipRanks’ Stock Analysis page.